- $520.64m
- $415.98m
- $7.00m
Annual balance sheet for Evommune, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Cash and Equivalents | ||
| Short Term Investments | ||
| Cash and Short Term Investments | 79.1 | 72 |
| Prepaid Expenses | ||
| Total Current Assets | 80 | 74 |
| Net Property, Plant And Equipment | 1.97 | 1.8 |
| Other Long Term Assets | ||
| Total Assets | 82.2 | 76.1 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Current Portion of Long Term Debt / Capital Leases | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 6.86 | 28 |
| Capital Lease Obligations | ||
| Total Long Term Debt | ||
| Total Debt | ||
| Total Other Liabilities | ||
| Total Liabilities | 10.6 | 28.5 |
| Redeemable Preferred Stock | ||
| Non Redeemable Preferred Stock | ||
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Other Equity | ||
| Total Equity | 71.7 | 47.5 |
| Total Liabilities & Shareholders' Equity | 82.2 | 76.1 |
| Total Common Shares Outstanding |